Bookmark Kaumudi Online  Bookmark this site  Editor@Kaumudi  |  Marketing  Print Advt rates  |  Calendar 2018        Go!    
 
 
September 23, Sunday 2018 1:48 PM       

       HEADLINES: Franco Mulackal should be subjected to lie detector test, says police                                              Fr. Mathew Manavath raises allegation against Kerala BJP                                              Body of toddler found                                              CM reaches office                                              Fr. Geevarghese defends his decision to join BJP                                              We did not have a choice, says ex-French President Hollande on Reliance getting Rafale offsets                                              “If church try to throw us out, we’ll face it”, say nuns                                              UN Secretary-General to visit India in October                                              Russia warns US it is 'playing with fire' with sanctions                                              Pak PM Imran hits out at India, calls its response "arrogant" for cancelling talks                                              Hasan, Asghar, Rashid fined 15 per cent of their match fees                                              Kaumudi Facebook
       SCI&TECH Next Article: Clearing the myths about osteoporosis  
       Aspirin a day may keep liver cancer away
 
         Posted on :18:27:33 Oct 21, 2017
   
A A
       Last edited on:18:27:33 Oct 21, 2017
         Tags: Aspirin a day may keep liver cancer away
 

WASHINGTON DC: Taking aspirin daily can reduce the risk of liver cancer, a new study suggested.

The researchers found that everyday aspirin therapy could significantly associate with a reduced risk in hepatitis B related liver cancer.

Hepatitis B is a viral infection that attacks the liver. HBV can be contracted through contact with an infected person's blood or other bodily fluid, and the infection can either be acute or chronic.

It has been estimated that around estimated 240 million people worldwide have chronic HBV. The findings also show Africa and Asia as the highest prevalence of the virus.

Previous studies also show that daily aspirin therapy -- which is often prescribed to prevent cardiovascular disease -- may also prevent the development of cancer.

However, on another note clinical evidence is being lacked for the effectiveness of aspirin therapy in preventing HBV-related liver cancer.

Researcher Teng-Yu Lee from the Taichung Veterans General Hospital conducted a nationwide cohort study to determine if aspirin therapy could, indeed, reduce liver cancer risk.

"Liver cancer is the second leading cause of cancer death worldwide, and HBV is the most prevalent risk factor in our region," said Dr. Lee who's the lead author of the study.

"HBV-related liver cancer is therefore a major public health issue with a severe socioeconomic impact," he stated.

Dr. Lee stated that therapies which reduce the risk of liver cancer like, nucleos(t)ide analogue therapy, do not completely eliminate the risk. Adding, he also mentioned that most HBV carriers are not indicated for antiviral therapy, so another effective way of reducing liver cancer risk needs to be developed.

"Aspirin has been investigated to explore its chemopreventive effect in cancers that are related to chronic inflammation, particularly in the prevention of colorectal cancer. However, clinical evidence supporting the chemopreventive effect of aspirin therapy on liver cancer remains limited. Therefore, we conducted a large-scale cohort study to evaluate the association of aspirin therapy with HBV-related liver cancer," he noted.

Retrieving past medical records for the study, they screened records of 204,507 patients with chronic hepatitis B, and excluded patients with other forms of infectious hepatitis, from the National Health Insurance Research Database between the year 1998 and 2012.

The past findings showed that 1,553 patients who continuously received daily aspirin for at least 90 days were randomly matched 1:4 with 6,212 patients who had never received anti- platelet therapy by means of propensity scores consisting of baseline characteristics.

The researchers analyzed both cumulative incidents of and hazard ratios for HCC development after adjusting for competing mortality.

Cumulative incidence of liver cancer in the group treated with aspirin therapy was significantly lower than that in the untreated group in five years.

The researchers in their multivariate regression analysis found that aspirin therapy was independently associated with reduced liver cancer risk.

"For effectively preventing HBV-related liver cancer, the findings of this study may help hepatologists treat patients with chronic HBV infection in the future, particularly for those who are not indicated for antiviral therapy. We are pursuing prospective investigations for further confirming the findings," stated Dr. Lee.

The study presented at The Liver Meeting held by the American Association for the Study of Liver Diseases (AASLD).

A A
       SCI&TECH
Next Article: Clearing the myths about osteoporosis
 
 
SCI&TECH HEADLINES
Pluto should be reclassified as a planet, reveals study  
Shared responsibility essential for conserving migratory species  
Microsoft releases Speech Corpus for three Indian languages  
Facebook likely to run on 100% renewable energy by 2020  
Can brain suppress the act of revenge?  
Kerala techies launch portal to facilitate relief measures  
Here's what you may not know about H2O  
Alexa will tell you when it has done its homework  
Students recreate horrific atomic bombings of Hiroshima using VR technology  
Study discovers compounds that can reverse cell ageing  
Online interactive courses on AI in trading, first time on internet  
Apple to fix devices damaged by Japan's floods for free  
IT industry should focus on developing new technologies  
Skype adds read receipts to chats  
Mobile app for replacement of transformers in Raj  
Kashmiri students make solar boat for Dal Lake  
NASA prepares to fly probe into Sun's scorching atmosphere  
Yoga helps against non-communicable diseases: WHO  
Spironolactone can help prevent acne: Study  
Older Amazonian forests help regulate global climate  
Goal conflict linked to depressive symptoms  
A new world: Top 10 new species for 2018  
Beat the risk of frailty with healthy heart  
Twitter to hide trolls that hurl abuse: Twitter CEO  
Fortnite is finally coming to Android  
 
Do you agree with Rahul's allegation against Modi over Rafale deal?
yes
 
no
 
no opinion
 
 
 
Home Kerala India World Business Sports Sci&Tech Education Automobile CityNews Movies Environment Letters 
© Copyright keralakaumudi Online 2011  |  Reproduction in whole or in part without written permission is prohibited.
Head Office Address: Kaumudi Buildings, Pettah P.O, Trivandrum - 695024, India.
Online queries talk to Deepu Sasidharan, + 91 98472 38959 or Email deepu[at]kaumudi.com
Customer Service -Advertisement Disclaimer Statement   |  Copyright Policy